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Risk prediction based on genomic profiles has raised a lot of attention recently. However, family history is usually ignored in genetic risk
prediction. In this study we proposed a statistical framework for risk prediction given an individual’s genotype profile and family history.
Genotype information about the relatives can also be incorporated. We allow risk prediction given the current age and follow-up period
and consider competing risks of mortality. The framework allows easy extension to any family size and structure. In addition, the pre-
dicted risk at any percentile and the risk distribution graphs can be computed analytically. We applied the method to risk prediction for
breast and prostate cancers by using known susceptibility loci from genome-wide association studies. For breast cancer, in the popula-
tion the 10-year risk at age 50 ranged from 1.1% at the 5th percentile to 4.7% at the 95th percentile. If we consider the average 10-year
risk at age 50 (2.39%) as the threshold for screening, the screening age ranged from 62 at the 20th percentile to 38 at the 95th percentile
(and some never reach the threshold). For women with one affected first-degree relative, the 10-year risks ranged from 2.6% (at the 5th
percentile) to 8.1% (at the 95th percentile). For prostate cancer, the corresponding 10-year risks at age 60 varied from 1.8% to 14.9% in
the population and from 4.2% to 23.2% in those with an affected first-degree relative. We suggest that for some diseases genetic testing
that incorporates family history can stratify people into diverse risk categories andmight be useful in targeted prevention and screening.Introduction
For complex diseases with substantial heritability, the
prediction of disease risk has been largely based on family
history information. However, because of the recent prog-
ress in genome-wide association studies (GWAS), an
increasing number of susceptibility variants for complex
diseases are being identified.1,2 The genotyping of these
variants is expected to contribute to risk prediction.
Genetic risk prediction has raised a lot of attention
recently, andmanycompanies (e.g., 23andMe,deCODEme,
Navigenics) are already offering such services. However,
family history is ignored in genetic risk prediction by these
companies. Familyhistory canoften (thoughnot always)be
obtained easily and at no extra cost. However, family
history is unable to stratify people into fine risk categories
because in most cases people either have a negative family
history or just have one or two close relatives with the
disease. On the other hand, the number of genotype
combinations from SNPs is large. For example, 5, 10, and
20 biallelic loci will give rise to 243 (35), 59,049, and
3,486,784,401 combinations respectively.
In addition, people with a positive family history have
a greater incentive to request genetic testing. Because
they have a higher baseline risk, the range of predicted
risks for their given genotype profile is usually larger
than that of other individuals without a family history of
the disease (this will be illustrated in later examples).
Therefore, a risk prediction algorithm that takes into
account both family history and an individual’s genotype
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family history and known susceptibility variants into risk
prediction; genotype information of relatives can also be
incorporated into the model. In addition, to account for
competing risks ofmortality, we allow risk prediction given
the current age and a period of follow up. The framework
we propose is very flexible and allows easy extension to
any family size and structure. One can readily extend the
model to handle markers in linkage disequilibrium (LD),
haplotypes, or multilocus genotypes (when interactions
are present). In addition, the predicted risk at any percen-
tile and the risk distribution graphs can be computed
analytically without simulations.
Our risk prediction framework is based on the liability
threshold model, which assumes a latent continuous
liability underlying each disease.3 The use of the liability
threshold model in risk prediction has more than 30 years
of history.4–6 For example, Mandell and Elston6 previously
proposed the use of the Pearson-Aitken (PA) formula in
estimating recurrence risks in relatives, and the same
formula is employed in our model. Our proposed frame-
work can thus be regarded an extension of these previous
works.
We apply the framework to breast cancer (MIM 114480)
and prostate cancer (MIM 176807) and discuss the possible
impact of genetic testing on screening based on family
history and known susceptibility variants. We computed
the lifetime risk and 10-year risk of breast and prostate
cancer at age 50 or 60 for people at different risk percen-
tiles. From these data, we estimated the age at which
screening should start. We found that the screening age,a; 2Genome Research Centre, University of Hong Kong, Hong Kong SAR,
ong Kong, Hong Kong SAR, China
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the absolute disease risks, and the number of individuals
that need to be screened in order to prevent one cancer
death (NNS) all vary considerably for different risk percen-
tiles, implying that genetic tests with family history might
be useful in risk stratification and targeted prevention of
some cancers.Material and Methods
Model Assumptions
Underlying the disease is a latent construct called liability (L),
which is determined by multiple genetic and environmental
factors and is normally distributed in the population with a
mean of 0 and a variance of 1; each disease-associated locus
explains a certain proportion of variance (Vg), and the aggregate-
over all disease-associated loci is defined as the heritability of
the disease. There is a threshold value (T) in liability, which
when exceeded leads to the development of disease.
The total liability L can be partitioned into two components,
a measurable liability (M), produced by known susceptibility vari-
ants, and another component (U), produced by genetic variants
yet-to-be discovered as well as environmental factors. That is L ¼
M þ U. The measurable liability,M, has a mean of 0 and a variance
of V in the population, so that it explains a proportion V of the
variance in the total liability L (which has a variance of 1).The
value V is equal to the sum of the variance in liability explained
(or heritability explained) by individual known loci. The method
of calculating Vg by a single locus is described in So et al.7 Note
that our model can also be generalized to take account of known
measurable environmental risk factors (e.g., smoking status, lipid
levels, etc.), but for simplicity of exposition, we assume here that
environmental factors are not measured. The appendices include
a brief discussion on the incorporation of environmental risk
factors into the prediction model.
In this study we also assume that the liability refers to a lifetime
diagnosis of the disease. Hence, the threshold value (T) is deter-
mined by the lifetime risk of disease in the population (denoted
by K). In notations T ¼ F1ð1 KÞ, where F1 is the inverse
normal distribution function. Also, the variance in liability
explained by known susceptibility variants is evaluated based on
lifetime risk and lifetime relative risk estimates as inputs. The risks
calculated are therefore lifetime disease risks. However, the method
can be generalized to take into account the current age of the
individual and predict risk in a specified period of time.
Construction of Measured Liability Score
We describe how to calculate the variance in liability explained
and the liability score for each genotype elsewhere.7 The method
allows any odds ratios for genotypes.
If we assume a multiplicative model of allelic effects (e.g., if Aa
has an odds ratio (OR) of 1.3 over aa, then AA will have an OR
of 1.32 ¼ 1.69), the liability score for the ith locus can also be
approximated by
ﬃﬃﬃﬃﬃ
Vi
p
(square root of the Vg by that locus) multi-
plied by the standardized genotype count (Gi). The total liability
score is then given by the sum of individual scores,
P
i
ﬃﬃﬃﬃﬃ
Vi
p
Gi.
Prediction of Disease Risk from Measured Liability
Score
The proportion of variance in liability explained by known genetic
variants, V, is directly related to our ability to predict the risk ofThe Amedisease in an individual from genotype information. Because
Cov(L,M) ¼ Var(M) ¼ V, we have from standard regression theory,
E(LjM¼m)¼m and Var(LjM¼m)¼ 1V. Hence, Pr(L>TjM¼m),
or the absolute risk of disease, can be obtained from the standard
normal distribution function once we know the liability score (m)
from the confirmed genetic variants.
Risk Prediction with Consideration of Family History
Modeling Affected Relatives
Here, we examine risk prediction by using known susceptibility
variants for individuals with a positive family history of disease.
For simplicity, we first consider the case of an individual with
one affected first-degree relative. The PA formula can be applied
to model the joint impact of family history and measured suscep-
tibility variants on disease risks. The PA formula describes how the
mean vector and covariance matrix of set of variables are distorted
by selection on a subset of the variables. In addition to the PA
formula, it is also possible to use multivariate integration for
modeling the effects of selection. The PA formula, however, is
simpler to implement (because numerical integration programs
are not needed) and enables explicit formulas to be given for the
results. We will focus on the use of PA formula, and details of
the alternative approach withmultivariate integration are detailed
in the Appendix A.
Consider three liability distributions including (1) the overall
liability of the individual’s First-degree relative (Lrel), (2) the
measurable liability of the individual (Mind), and (3) the overall
liability of the individual (Lind). The mean vector of the above
three liability distributions ½Lrel;Mind;Lind T before selection is
simply [0,0,0]T. The covariance matrix is
S ¼
2
4 1 V=2 h=2V=2 V V
h=2 V 1
3
5;
where the total Vg by the known susceptibility variants is denoted
by V and the heritability denoted by h. For simplicity of exposi-
tion, we shall assume in this paper that heritability refers to the
narrow-sense (additive) heritability only. Nonadditive effects are
assumed to be negligible. One can relax this assumption by
including dominant effects as well, but the covariance of parent-
child and siblings will then be different.
The selection for affected first-degree relatives changes the distri-
bution of Lrel from a standard normal to a truncated normal distri-
bution in which the truncation point equals T. From theories of
truncated normal distribution, the new mean and variance of
Lrel are
EðLrel;newÞ ¼ fðTÞ
1 FðTÞ ¼ a; var ðLrel;newÞ ¼ 1 a
2 þ aT ¼ b:
One can then apply PA formula as described above to calculate
the mean and covariance matrix of Mind and Lind after selection
on Lrel. Then we perform the second selection based on the known
measurable liability of the individual, denoted by mI. The PA
formula is applied again to give the new mean and variance of
the individual’s overall liability Lind. The results are given below.
Mean of Lind after selection (mind;fam) (first-degree relative
affected)
¼ ah
2
þ

V  ð1 bÞVh
4

1
V  ð1 bÞV2=4

mI  aV
2

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Variance of Lind after selection (s
2
ind; fam) (first-degree relative
affected)
¼ 1 ð1 bÞ

h2
4



V  ð1 bÞVh
4
2
1
V  ð1 bÞV2=4

(Equation 2)
The absolute risk of disease for the individual is the probability
that the overall liability (a normally distributed variable with the
above mean and variance) exceeds the threshold, T.
PrðDiseaseÞ ¼ 1F
0
B@T  mind; famﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
s2ind; fam
q
1
CA:
Using the same approach, we can derive the risk estimate of an
individual who has an affected second-degree relative. It can be
shown that Lind, given family history in which a second-degree
relative is affected and the individual’s measured liability, has
the following mean and variance:
The mean of Lind after selection (second-degree relative
affected) is
ah
4
þ

V  ð1 bÞVh
16

1
V  ð1 bÞV2=16

mI  aV
4

:
The variance of Lind after selection (second-degree relative
affected) is
¼ 1 ð1 bÞ

h2
16



V  ð1 bÞVh
16
2
1
V  ð1 bÞV2=16

:
Extension to Arbitrary Family Structure
The above methods can be readily extended to arbitrary family
structures and any number of affected and unaffected relatives.
The covariance structure of the liabilities needs to be adjusted ac-
cording to the family structure. Further examples of risk prediction
with the PA formula will be given in later sections.
Taking into Account Current Age and Predicting Risk in a Specified Period
of Time
This is an extension of our previous work on age-conditional risk
predictionwithoutconsidering familyhistory.8Note thatweassume
proportional hazards, that is the hazard ratio of disease due to posi-
tive family history, is constant regardless of the subject’s age.
The absolute disease risk for an individual with a current age of
a in the next s years is
pðs; a;RÞ ¼ R
Z aþs
a
lðbÞ exp


Z b
a
ðRlðxÞ þ mðxÞÞdx

db
(Equation 3)
The PA formula enables us to estimate the lifetime risk of an indi-
vidual given his or her family history and known genetic factors.
This gives pðs; a; RÞ. Because the disease incidence function (l(x),
where x is the age) and the netmortality function (m(x)) are known,
the only unknown is the hazard ratio R. The above equation can
be solved numerically for R; then one can substitute any value of
startingage (a) andperiodof followup (s) into the formula toobtain
the relevant risk estimates.
Risk Distribution in Individuals with an Affected
First-Degree Relative, Given a Set of Known
Susceptibility Variants
Suppose we predict an individual’s risk based on two pieces of
information: (1) a set of known genes and (2) whether the person
has an affected first-degree relative. We ignore more complex
family histories for simplicity. What is the distribution (i.e., the550 The American Journal of Human Genetics 88, 548–565, May 13,probability density function [pdf]) of predicted risks in those
with an affected first-degree relative?
We have described before the mean of overall liability after
selection by positive family history (see Equations 1 and 2). The
predicted absolute risk (r) is
r ¼ 1F
0
B@T  mind; famﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
s2ind; fam
q
1
CA:
The variable mI in Equation 1 is equivalent to z, which will be
used below to represent the measurable liability. For notational
simplicity, we define
w ¼ ah=2 q ¼

V  ð1 bÞVh
4

1
V  ð1 bÞV2=4

; s ¼ aV=2;
r ¼ 1F
0
B@T  ½w þ qðz sÞﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
s2ind; fam
q
1
CA;
and
dr
dz
¼ f
0
B@T  ½w þ qðz sÞﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
s2ind; fam
q
1
CA
0
B@ qﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
s2ind; fam
q
1
CA;
z can be expressed as
z ¼ F1ðpÞ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃvrel; affp þ mrel; aff ;
where vrel;aff and mrel;aff are the variance and mean of measurable
liability, respectively, for an individual (Mind) who has an affected
first-degree relative. p is the percentile of the measurable liability
given an affected first-degree relative. We have vrel;aff ¼
V  ð1 bÞðV2=4Þ and mrel;aff ¼ aV/2.
Note that
dz
dp
¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
vrel; aff
p
f

F1ðpÞ
Thus giving
dp
dr
¼ 1=

dr
dz
 dz
dp

:
dp/dr is the derivative of the cumulative density function (cdf) of
predicted risks and is equal to the pdf. The method can be
extended to deal with any family structure and any number of
affected relatives. Knowing the predicted risk distribution has
practical implications. For example, the distribution allows us to
assess the proportion of people exceeding certain risk thresholds
for screening or interventions.
Risk Prediction with Consideration of Measurable
Liability of Relatives
We have described how to predict disease risk for an individual
with positive family history and have a set of susceptibility vari-
ants genotyped. The methodology can be extended naturally to
incorporate the measurable liability of relatives. For example,
some of the relatives might also have been genotyped on a set of
risk genes, and this information can be used to further improve
risk prediction for the individual.
We will illustrate with an example how themeasurable liabilities
of relatives can be incorporated into the risk prediction algorithm.
Suppose a first-degree relative is affected with the disease. Both the
relative and the individual are tested on the same set of known2011
susceptibility variants. To predict the individual’s risk, we have to
consider four liability distributions: (1)Lrel, the overall liability of
the relative; (2)Mrel, the measurable liability of the relative;
(3)Mind, the measurable liability of the individual; and (4)Lind,
the overall liability of the individual. The vector (Lrel, Mrel, Mind,
Lind) has the following mean and covariance matrix:
m ¼
2
664
0
0
0
0
3
775S ¼
2
664
1 V V=2 h=2
V V V=2 V=2
V=2 V=2 V V
h=2 V=2 V 1
3
775:
The PA formula was applied iteratively for the following three
levels of selection: (1) the relative being affected (Lrel > T), (2)
the known measurable liability of the relative (Mrel), and (3) the
known measurable liability of the individual (Mind). The details
of the calculation are given in the Appendix A.
After the selections, the mean and variance of the individual’s
overall liability are
~m final ¼
ah
2
 aV½1 ð1 bÞh
2½1 ð1 bÞV þ
1
2

1 ð1 bÞh
1 ð1 bÞV  1

mR þmI
and
~Vfinal ¼ 1 ð1 bÞh
2
4
 ½V  ð1 bÞVh
2
4
	
V  ð1 bÞV2
 3V4 ;
where mR and mI are the measurable liabilities of the relative and
the individual, respectively. The absolute risk of disease for the
individual is the probability that the overall liability (a normally
distributed variable with the above mean and variance) exceeds
the threshold, T.
The individual’s and the relative’s measurable liabilities have
different impacts on the final predicted risk, which can be deduced
from the above results. It is obvious that if an individual has a high
measurable liability, he or she will also have a high overall liability
and higher disease risk. But what about the measurable liability of
the affected relative? The question will be resolved by the
following derivations.
Because the Vg by genetic variants cannot exceed the total heri-
tability ðhRVÞ and b is the variance of the truncated standard
normal distribution, b < 1, then
ð1 bÞhRð1 bÞV
1 ð1 bÞÞh%1 ð1 bÞV
1
2

1 ð1 bÞh
1 ð1 bÞV  1

%0
:
Because the above factor that accompanies mR is always smaller
than or equal to 0, a highermeasurable liability of the affected rela-
tive leads to a lower predicted risk for the individual.
This phenomenon can also be explained intuitively. If it is
known that the relative harbors a lot of risk variants, then on
average the rest of the variants that are passed onto his or her chil-
dren or other relatives should be more protective. (The measured
risk genes already raise the disease risk to a sufficiently high level.)
On the other hand, if it is known that measured genotypes are
mostly protective, but the relative is still affected, then on average
the ungenotyped variants are likely to contain more risk variants.
Here, we also consider the case when a first-degree relative is
affected and his or her measurable liability is known. The individ-
ual’s measurable liability is, however, not known. Conditioned on
these factors, the mean and variance of the index individual’s
overall liability areThe Ame~m ¼ ah
2
þ V  ð1 bÞVh
2
	
V  ð1 bÞV2
ðmR  aVÞand
ð1 bÞh2 ½V  ð1 bÞVh2~V ¼ 1
4

4
	
V  ð1 bÞV2
;
respectively. The derivation is very similar to above. In this case,
the higher the relative’s measurable liability, the bigger the risk
for the index individual (see the Appendix A for the proof).Dealing with Continuous Risk Factors
Our original motivation for evaluating the Vg was to quantify
the contribution of individual genetic variants to heritability.
However, the same concept can also be extended to continuous
risk factors. This extension would provide us with a unifying statis-
tical framework for risk prediction such that our proposed method
could deal with all types of risk factors, categorical or continuous.
The details are given in the Appendix A. Briefly, we can consider
that the continuous risk factor is composed of a very large number
of categories, as opposed to only three categories for a biallelic
marker.Application to Real Examples: Breast and Prostate
Cancer Risk Estimates and Implications for Screening
We illustrate the above methodologies by applying them to breast
and prostate cancers. The odds ratio estimates for the two diseases
were extracted mainly from the GWAS catalog maintained by
the National Human Genome Research Institute (NHGRI),2 com-
plemented by a manual PubMed search. We included only genetic
variants passing the genome-wide significance level (7.23 108).9
The details of the included susceptibility variants are described in
another manuscript.7 Briefly, a total of 13 SNPs were included for
breast cancer and 30 were included for prostate cancer. The details
are given in Tables S1 and S2 (available online). Incidence and
mortality data (for the years 2004–2006) were extracted from the
Surveillance, Epidemiology and End Results (SEER) database, es-
tablished by the National Cancer Institute in the United States.
Risk estimates were based on a white population from the U.S.,
and only female breast cancers were considered.
The procedures for risk estimation were as follows. We first con-
verted the reported odds ratios to lifetime relative risks, taking into
account competing risks. On the basis of the lifetime risks and the
lifetimeRR, the totalVgwas computed. This is also equal to the vari-
ance of the measurable liability. Then we applied the PA formula to
handle the covariance between the relevant liability distributions.
In fact, the formulas for themore typical cases (e.g., one first-degree
relative is affected) have been derived. The lifetime risks for people
at different percentiles were computed. Besides the lifetime risk,
we also calculated the 10-year absolute risk for women whose
current age was 50, for each percentile. To do so, we deduced the
incidence rate ratio (i.e., the hazard ratio) from the lifetime risk
estimates according to Equation 3. The age-specific absolute risk
for any follow-up periods could then be obtained. We performed
the same risk-estimation procedure for women with one affected
first-degree relative whose genotype profile (i.e., measurable
liability) was also known. The algorithm is summarized in Table 1.
Next, we assessed the implications of genetic risk prediction
for screening and chemoprevention, inspired by the analysis in
Pharoah et al.10 Breast cancer screening by mammography has
been shown to provide benefits.11 The US Preventive Servicesrican Journal of Human Genetics 88, 548–565, May 13, 2011 551
Table 1. Algorithm for Predicting Lifetime Risk and Age-
Conditional Risk within a Certain Time Interval with Family History
Information
Step Procedure
1 Use the competing risk formula to calculate the lifetime RR for the
genotypes in each variant (i.e., calculate the lifetime risk for each
genotype by using POR, then divide the lifetime risk of each group
by that of a baseline group to obtain the lifetime RR).a
2 Compute the Vg of all variants; Vg is calculated with overall
lifetime risk and the allele frequency and lifetime RR of genotypes
as inputs. This forms the measurable liability.
3 Use the PA formula to take into account covariance between total
and measurable liability, and obtain the predicted lifetime risk.
4 Deduce the R for each year from the overall lifetime absolute risk
by solving the competing risk equation (Equation 3).
5 Knowing R, we can estimate the risk by using any start age
and specifying any time period.
The following abbreviations are used: RR, relative risk; POR, prevalence odds
ratio; Vg, variance explained; R, the hazard ratio; PA, Pearson-Aitken. Please
refer to So and Sham8 for more details concerning the calculation of lifetime
RR. Note that both the heritability and measurable liability refers to liability
to a lifetime diagnosis of the disease.
a Assumes the genetic loci to have constant effects on liability and hazard ratios
regardless of age.Task Force (USPSTF) recommends biennial mammography
screening for women between 50 and 74 years old.11 The UK
National Health Service also offers screening to women above
age 50. We calculated the average 10-year risk for a 50-year-old
women to develop breast cancer as an approximate risk threshold
for mammography screening, as in Pharoah et al.10 The 10-year
risk is 2.39%, and we evaluated the age at which women at
different risk percentiles would reach this risk level. Adding to
the work of Pharoah et al.,10 we have updated the number of
loci to 13 and described in detail the methodology to compute
the absolute risks, accounting for competing causes of mortality
(the methods for deriving the absolute risks were not detailed by
Pharoah et al.10). Importantly, we extended the previous work to
incorporate family history and the relatives’ genetic profile in
risk prediction. The NNS to prevent one cancer death was esti-
mated. Unlike Pharoah et al.10, we provided a general analytic
approach to perform the calculations without the need to consider
all genotype combinations. The method was also applied to pros-
tate cancer. It is also much easier to evaluate the risks at different
percentiles with our approach, because genotype combinations
are conceptualized as the measurable liability.
Here, we briefly describe the concept of the NNS to prevent one
cancer death.12 NNS is an extension of the idea of number needed
to treat. It is equal to 1 divided by the absolute reduction in
mortality rate from the disease, if one compares the screening
with the no-screening group. Following our previous calculations,
we considered the NNS of a group of 50-year-old women with
10-year follow up. Instead of estimating the age at which one
should start screening, we changed the angle of view and consid-
ered a group of women who start screening at the same age (50)
and calculate how many women need to be screened such that
one cancer death can be avoided. The rate ratio for death from
breast cancer in the screening group is taken as 0.86.13 In other
words, when compared to women who do not receive any
screening, the mortality rate from breast cancer is 14% lower in
the screening group. This is, however, only the proportional
decrease in mortality. The absolute mortality reduction is equal552 The American Journal of Human Genetics 88, 548–565, May 13,to the actual 10-year mortality rate in the unscreened groupmulti-
plied by 14%. One divided by this absolute mortality reduction is
taken as the NNS in the general population (we assume the 50th
percentile represents the general population).
Note that the NNS is lower if the disease is more common, for
example in high-risk groups. We assumed that the susceptibility
variants and family history do not affect the mortality and the
mortality rate ratio is constant. As a result, if the condition is ten
times more common in a subgroup, the absolute mortality reduc-
tion is also ten times higher and the NNS will be 1/10 of the
control group. Using this principle, we computed the NNS at
different risk levels as derived from the genotype profile and
family history.
It has been shown that the risk of invasive breast cancer could be
reduced by the drugs tamoxifen and reloxifene.13 The Food and
Drug Administration has approved the use of these drugs for
high-risk women, including those with a five-year cancer risk of
1.66% or more.13 Hence, we also considered this threshold and
estimated the age at which this threshold will be passed.
A similar set of analyses was also performed on prostate cancer.
However, for prostate cancer, the benefit of screening is less clear.
Prostate-specific antigen (PSA) testing and digital rectal examina-
tion are commonly employed for screening. The USPSTF judged
that there is insufficient evidence to assess the balance of benefits
and harms of screening for men below age 75. Screening is not
recommended above age 75.14,15 The American Cancer Society
recommended that asymptomatic men with at least 10-year life
expectancy make an informed decision with their health care
provider as to whether they should receive screening for prostate
cancer after discussing the risks and benefits of screening with
their health care provider. Average-risk men should receive such
information starting at age 50.16
Similar to our calculations for breast cancer risk, we estimated
the average 10-year risk of prostate cancer at age 50 as the risk
threshold for screening. We repeated the procedures for risk
estimation used in the breast cancer example, except that the
10-year risk at age 60 was also computed because of the later onset
of the disease. The NNS was computed based on the consideration
of 60-year-old men with 10 years of follow up. The rate ratio for
death from prostate cancer in those who are screened was taken
to be 0.80.17Construction of Confidence Intervals
To provide a sense of the uncertainty of risk estimates, we con-
structed the confidence intervals of the predicted risks by a simula-
tion approach. The standard deviation of log odds ratio (ln OR)
for each SNP is derived from its confidence interval, and ln OR is
assumed to follow a normal distribution. A random ln OR is simu-
lated for every SNP in each run, and the entire procedure for risk
estimation is repeated. A total of 1,000 simulations are performed.Results
Table 2 shows the absolute risks of breast cancer at different
risk percentiles in the general population. The total Vg by
the known genetic variants is 5.70%. The predicted life-
time risk ranged from 5.7% at the 5th percentile to
22.1% in the 95th percentile. The range of 10-year risks
at age 50 is smaller. Women at the 5th percentile had a
risk of 1.1%, whereas those at the 95th percentile had a2011
Table 2. Predicted Risk of Breast Cancer in the General Population from Genetic Profiles
Percentile
Lifetime Risk
(95% CI)
Incidence
Rate Ratio
(95% CI)
10-Year-Risk at
Age 50 (95% CI)
Age at which
10-Year Risk > 2.39%
Age at which
5-Year Risk > 1.66% NNS
5 0.057 (0.049–0.061) 0.46 (0.39–0.49) 0.011 (0.009–0.012) NA NA 3913
10 0.068 (0.061–0.072) 0.55 (0.49–0.58) 0.013 (0.012-0.014) NA NA 3265
20 0.084 (0.077–0.087) 0.68 (0.63–0.71) 0.016 (0.015–0.017) 61.7 NA 2643
30 0.096 (0.091–0.099) 0.79 (0.75–0.81) 0.019 (0.018–0.019) 55.9 NA 2281
40 0.108 (0.104–0.110) 0.90 (0.86–0.91) 0.021 (0.021–0.022) 52.6 65.5 2018
50 0.120 (0.118–0.121) 1.00 (0.98–1.01) 0.024 (0.024–0.024) 49.9 60.3 1805
60 0.133 (0.133–0.133) 1.12 (1.12–1.12) 0.027 (0.027–0.027) 47.1 57.4 1619
70 0.148 (0.147–0.150) 1.26 (1.25–1.28) 0.030 (0.030–0.030) 44.5 54.8 1445
80 0.167 (0.164–0.172) 1.44 (1.41–1.49) 0.034 (0.034–0.035) 42.1 51.6 1269
90 0.195 (0.190–0.206) 1.71 (1.67–1.82) 0.041 (0.039–0.043) 39.6 47.1 1067
95 0.221 (0.214–0.236) 1.97 (1.90–2.14) 0.047 (0.045–0.050) 38.0 44.4 930
The percentile column refers to the percentile of the measurable liability derived from known susceptibility variants. The following abbreviations are used: CI,
confidence interval; NNS, number of individuals that need to be screened in order to prevent one cancer death; NA, not applicable. Because of competing risks
of mortality, the absolute risk will not reach the designated threshold in these groups of women. Also note that the incidence rate ratio is computed with reference
to the general population.risk of 4.7%. If we consider the average 10-year risk at age
50 (2.39%) as the threshold for screening, the age at which
such a threshold is reached differs considerably at different
percentiles. The age ranges from 62 for women at the 20th
percentile to 38 at the 95th percentile. Women at or below
the 15th percentile will never meet this threshold because
of competing risks of mortality. Similarly, the age at which
the 5-year risk exceeds 1.66% differs considerably for
women at different risk percentiles.
The risk estimates for women with one affected first-
degree relative are shown in Table 3. The risks are higher
than in the general population. The actual risks range
from 13.2% at the 5th percentile to 35.4% at the 95thTable 3. Predicted Risk of Breast Cancer in Women Having One Affec
Percentile
Lifetime Risk
(95% CI)
Incidence Rate Ratio
(95% CI)
10-Year-Ris
at Age 50 (
5 0.132 (0.119–0.138) 1.11 (0.99–1.17) 0.026 (0.024
10 0.150 (0.138–0.156) 1.28 (1.17–1.33) 0.030 (0.028
20 0.175 (0.165–0.179) 1.51 (1.43–1.55) 0.036 (0.034
30 0.194 (0.187–0.197) 1.70 (1.63–1.73) 0.040 (0.039
40 0.211 (0.207–0.213) 1.87 (1.83–1.89) 0.044 (0.043
50 0.228 (0.226–0.229) 2.05 (2.03–2.06) 0.048 (0.048
60 0.246 (0.245–0.246) 2.24 (2.23–2.25) 0.053 (0.052
70 0.265 (0.263–0.269) 2.45 (2.43–2.50) 0.057 (0.057
80 0.289 (0.286–0.297) 2.72 (2.68–2.82) 0.064 (0.063
90 0.324 (0.318–0.338) 3.13 (3.06–3.31) 0.073 (0.071
95 0.354 (0.345–0.374) 3.51 (3.40–3.77) 0.081 (0.079
The incidence rate ratio is computed with reference to the general population. T
individuals that need to be screened in order to prevent one cancer death.
The Amepercentile. The relative risk when comparing women at
the 5th and the 95th percentile is smaller for those with
family history (2.7 times versus 3.9 times), but the range
is larger (22.2% versus 16.3%). The age at which the
10-year risk exceeds the threshold (2.39%) ranges from
47 for women at the 5th risk percentile to 33 for women
at the 95th percentile.
The NNS vary considerably across different risk levels.
The NNS ranges from 930 (the risk at the 95th percentile)
to 3913 (the risk at the 5th percentile) in the population.
For women with a family history of breast cancer, the risks
are higher and the NNS is reduced. The range is from 532
to 1624.ted First-Degree Relative from Genetic Profiles
k
95% CI) NNS
Age at which
10-Year Risk > 2.39%
Age at which
5-Year Risk > 1.66%
-0.028) 1634 47.3 57.6
-0.032) 1420 44.2 54.4
-0.037) 1206 41.3 50.3
-0.041) 1075 39.7 47.3
-0.045) 978 38.5 45.2
-0.048) 896 37.6 43.8
-0.053) 823 36.8 42.7
-0.059) 753 36.0 41.6
-0.066) 680 35.1 40.6
-0.077) 594 34.0 39.2
-0.087) 532 33.1 38.3
he following abbreviations are used: CI, confidence interval; NNS, number of
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Table 4. Predicted Risk of Breast Cancer in Women Having One Affected First-Degree Relative, with Consideration of the Relative’s
Genotype Profile
Percentile
(Relative)
Percentile
(Index Individual)
Lifetime Risk
(95% CI)
Incidence Rate Ratio
(95% CI)
10-Year-Risk
at Age 50
(95% CI)
Age at which
10-Year
Risk > 2.39%
Age at which
5-Year
Risk > 1.66%
5 5 0.141 (0.128–0.147) 1.19 (1.07–1.25) 0.028 (0.026–0.030) 45.7 56.0
10 5 0.137 (0.124–0.143) 1.16 (1.04–1.21) 0.028 (0.025–0.029) 46.4 56.7
30 5 0.129 (0.115–0.135) 1.08 (0.96–1.14) 0.026 (0.023–0.027) 48.0 58.3
50 5 0.123 (0.110–0.130) 1.03 (0.91–1.09) 0.025 (0.022–0.026) 49.2 59.5
70 5 0.118 (0.104–0.124) 0.99 (0.86–1.04) 0.024 (0.021–0.025) 50.4 61.0
90 5 0.111 (0.097–0.117) 0.92 (0.80–0.98) 0.022 (0.019–0.023) 52.0 63.8
95 5 0.107 (0.093–0.114) 0.89 (0.77–0.95) 0.021 (0.018–0.023) 52.8 66.2
5 10 0.162 (0.151–0.167) 1.39 (1.29–1.44) 0.033 (0.031–0.034) 42.6 52.3
10 10 0.158 (0.146–0.163) 1.35 (1.25–1.40) 0.032 (0.030–0.033) 43.2 53.1
30 10 0.149 (0.137–0.154) 1.27 (1.16–1.32) 0.030 (0.028–0.031) 44.4 54.6
50 10 0.143 (0.131–0.148) 1.21 (1.10–1.26) 0.029 (0.026–0.030) 45.3 55.7
70 10 0.137 (0.125–0.143) 1.16 (1.04–1.21) 0.028 (0.025–0.029) 46.3 56.7
90 10 0.129 (0.116–0.135) 1.08 (0.97–1.14) 0.026 (0.023–0.027) 48.0 58.2
95 10 0.125 (0.112–0.131) 1.05 (0.93–1.11) 0.025 (0.022–0.026) 48.8 59.1
5 90 0.366 (0.357–0.386) 3.66 (3.54–3.93) 0.085 (0.082–0.091) 32.8 38.0
10 90 0.359 (0.350–0.378) 3.57 (3.46–3.82) 0.083 (0.080–0.088) 33.0 38.2
30 90 0.345 (0.337–0.362) 3.39 (3.30–3.61) 0.079 (0.077–0.084) 33.4 38.6
50 90 0.335 (0.328–0.351) 3.27 (3.19–3.47) 0.076 (0.074–0.080) 33.6 38.9
70 90 0.326 (0.319–0.340) 3.16 (3.08–3.33) 0.073 (0.072–0.077) 33.9 39.2
90 90 0.312 (0.307–0.325) 2.99 (2.93–3.14) 0.070 (0.068–0.073) 34.3 39.7
95 90 0.306 (0.301–0.318) 2.92 (2.86–3.06) 0.068 (0.067–0.071) 34.5 39.9
5 95 0.401 (0.389–0.426) 4.13 (3.97–4.51) 0.095 (0.091–0.103) 32.0 37.1
10 95 0.394 (0.382–0.419) 4.03 (3.88–4.39) 0.093 (0.089–0.101) 32.1 37.2
30 95 0.379 (0.369–0.402) 3.84 (3.70–4.15) 0.089 (0.086–0.095) 32.5 37.6
50 95 0.369 (0.359–0.391) 3.71 (3.58–4.00) 0.086 (0.083–0.092) 32.7 37.9
70 95 0.359 (0.350–0.380) 3.58 (3.46–3.85) 0.083 (0.080–0.089) 33.0 38.1
90 95 0.345 (0.337–0.364) 3.40 (3.30–3.63) 0.079 (0.077–0.084) 33.4 38.6
95 95 0.339 (0.331–0.356) 3.31 (3.22–3.53) 0.077 (0.075–0.082) 33.5 38.8
CI is an abbreviation for confidence interval.Another interesting point to note is that if we compare
the lifetime risk of all women against those with an
affected first-degree relative at every risk percentile, the
ratio of risks decreases with higher percentiles (Table S3).
Intuitively, when a woman is at a high-risk percentile,
she has already possessed many of the risk genotypes
that would account for her familial risk. Hence, the
increase in risk because of positive family history will be
smaller than average.
Finally, for individuals with an affected first-degree rela-
tive, we considered adding the affected relative’s genotype
profile to the risk prediction model (Table 4 and Table S4).
We assumed both the individual and the relative were554 The American Journal of Human Genetics 88, 548–565, May 13,genotyped on the same set of susceptibility variants. Add-
ing the relative’s genomic profile helps to further stratify
the individuals’ risks into finer categories. For instance,
a woman at the 95th risk percentile might have a predicted
risk ranging from 33.9% to 40% after considering her rela-
tive’s risk percentile. The highest and lowest predicted risks
are from the most discordant pairs (one at 5th and the
other at 95th percentile). Intuitively, if the relative is at a
high percentile of the measured liability (reflecting known
genes), the unmeasured liability (reflecting unknown
genes) tends to be lower, and the individual will have
a lower risk. The age at which the 10-year predicted risks
exceed the threshold of 2.39% also differs, the difference2011
Figure 1. Plots of Predicted Risks of Breast Cancer in the
General Population and in Individuals with a Family History of
Disease and with One Affected First-Degree Relative
Top: The probability density functions of predicted risks. Middle:
The predictiveness curve (predicted risk plotted against the risk
percentile). Bottom: the cumulative density functions of predicted
risks. The horizontal line in the middle graph represents the
average lifetime risk in the whole population. People with an
affected first-degree relative are denoted by ‘‘Fam Hx þve.’’
Figure 2. Ten-Year Risk of Breast Cancer at Different Risk
Percentiles for the General Female Population
The horizontal line represents the average 10-year risk of breast
cancer for a 50-year-old woman.
Figure 3. Ten-Year Risk of Breast Cancer at Different Risk
Percentiles for Women with One Affected First-Degree Relative
The horizontal line represents the average 10-year risk of breast
cancer for a 50-year-old woman.being larger for lower-risk individuals. This is because their
risks increase more slowly with age, whereas the high-risk
women pass the threshold quite early in their lives. For
women at the 5th percentile, the age at which their
10-year risks pass the threshold ranges from 45.7 to 52.8
when the relative’s risk percentile ranges from the 5th to
the 95th.The AmeFigure 1 shows the distribution of predicted risks in the
general population and in those with one affected first-
degree relative. Three types of graphs are shown, including
the risk distribution (or probability density function), the
plot of predicted risk versus risk percentile (predictiveness
curve), and the cumulative density of risks. Figures 2
and 3 show the 10-year risk of breast cancer at different
ages, in the population and within those with an affected
first-degree relative. The curve goes down at older ages
because of competing risks of mortality that reduce the
absolute risk of breast cancer. From Figure 2, it is clear
that a woman might never reach the risk threshold for
screening. The graphs also show the rate of increase in pre-
dicted risks with age; there are steeper curves for people at
higher percentiles.
The observations and conclusions from analyses on
prostate cancer are similar to those for breast cancer (seerican Journal of Human Genetics 88, 548–565, May 13, 2011 555
Table 5. Predicted Risk of Prostate Cancer in General Population
Percentile
Lifetime Risk
(95% CI)
Incidence Rate Ratio
(95% CI)
10-Year Risk at Age 50
(95% CI)
10-Year Risk at Age 60
(95% CI) NNS
Age at which
Risk > 2.11%
5 0.044 (0.043–0.053) 0.29 (0.28–0.35) 0.006 (0.006–0.007) 0.018 (0.017–0.021) 5477 64.3
10 0.059 (0.057–0.068) 0.39 (0.38–0.45) 0.008 (0.008–0.010) 0.023 (0.023–0.027) 4103 58.5
20 0.081 (0.079–0.089) 0.54 (0.53–0.60) 0.012 (0.011–0.013) 0.033 (0.032–0.036) 2949 54.8
30 0.100 (0.099–0.108) 0.69 (0.67–0.74) 0.014 (0.014–0.016) 0.041 (0.040–0.044) 2353 52.8
40 0.120 (0.119–0.125) 0.83 (0.82–0.87) 0.017 (0.017–0.018) 0.049 (0.049–0.051) 1956 51.3
50 0.140 (0.139–0.143) 0.98 (0.98–1.01) 0.021 (0.021–0.021) 0.058 (0.058–0.059) 1656 50.1
60 0.162 (0.162–0.163) 1.16 (1.16–1.17) 0.024 (0.024–0.025) 0.068 (0.068–0.068) 1411 49.0
70 0.189 (0.186–0.189) 1.38 (1.36–1.38) 0.029 (0.029–0.029) 0.080 (0.079–0.080) 1196 48.0
80 0.223 (0.216–0.224) 1.67 (1.61–1.68) 0.035 (0.034–0.035) 0.097 (0.093–0.097) 994 46.9
90 0.275 (0.261–0.278) 2.17 (2.03–2.19) 0.045 (0.042–0.046) 0.123 (0.116–0.125) 779 45.6
95 0.323 (0.302–0.327) 2.66 (2.43–2.71) 0.055 (0.051–0.056) 0.149 (0.137–0.151) 645 44.6
The incidence rate ratio is computed with reference to the general population. The following abbreviations are sued: CI, confidence interval; NNS, number of
individuals that need to be screened in order to prevent one cancer death.Tables 5 and 6; Table S5; and Figures S1, S2, and S3). The
total Vg for prostate cancer is higher than that for breast
cancer, and the range of the predicted risks is larger. For
men with an affected first-degree relative, the age at which
10-year risk exceeds the threshold (2.11%) ranges from 42
at the 95th percentile to 53 at the 5th percentile. For the
general population, the corresponding age range is from
45 to 64. Notably, the 10-year risks at age 60 vary widely.
The risks range from 4.2% (5th percentile) to 23.2%
(95th percentile) in those with an affected first-degree rela-
tive and from 1.8% to 14.9% in the population. It is also
worth noting that the NNS varies substantially from 645
(95th percentile) to 5477 (5th percentile) in the population
and from 414 to 2282 in those with an affected first-degree
relative. These results suggest that it might be more cost-Table 6. Predicted Risk of Prostate Cancer in Men Having One Affect
Percentile
Lifetime Risk
(95% CI)
Incidence Rate Ratio
(95% CI)
10-Year Risk a
(95% CI)
5 0.103 (0.100–0.118) 0.71 (0.68–0.82) 0.015 (0.014–0.
10 0.128 (0.125–0.142) 0.89 (0.87–1.00) 0.019 (0.018–0.
20 0.163 (0.161–0.174) 1.17 (1.15–1.26) 0.025 (0.024–0.
30 0.192 (0.190–0.200) 1.41 (1.39–1.48) 0.030 (0.029–0.
40 0.219 (0.218–0.225) 1.64 (1.63–1.69) 0.034 (0.034–0.
50 0.246 (0.246–0.249) 1.89 (1.88–1.91) 0.039 (0.039–0.
60 0.275 (0.274–0.275) 2.16 (2.16–2.16) 0.045 (0.045–0.
70 0.308 (0.303–0.309) 2.50 (2.44–2.50) 0.052 (0.051–0.
80 0.348 (0.338–0.350) 2.94 (2.82–2.96) 0.061 (0.058–0.
90 0.406 (0.389–0.410) 3.65 (3.43–3.70) 0.075 (0.070–0.
95 0.456 (0.432–0.461) 4.36 (4.00–4.43) 0.089 (0.082–0.
The incidence rate ratio is computed with reference to the general population. T
individuals that need to be screened in order to prevent one cancer death.
556 The American Journal of Human Genetics 88, 548–565, May 13,effective to screen high-risk individuals as stratified by
their genotype and family history.
We also observed that for people with one affected first-
degree relative but at the lowest risk percentiles (<10th),
their predicted lifetime risks are even lower than the
median population lifetime risk. The influence of the
known susceptibility loci begins to outweigh that of a
positive family history.Discussion
By considering the connections between the variance
(heritability) explained and absolute risk based on the
liability threshold model, we have proposed a statisticaled First-Degree Relative
t Age 50 10-Year Risk at Age 60
(95% CI) NNS
Age at which 10-Year
Risk > 2.11%
017) 0.042 (0.041–0.048) 2282 52.6
021) 0.053 (0.052–0.059) 1818 50.8
026) 0.069 (0.067–0.074) 1401 49.0
031) 0.082 (0.081–0.086) 1172 47.9
035) 0.095 (0.094–0.098) 1012 47.0
040) 0.108 (0.108–0.110) 887 46.3
045) 0.123 (0.123–0.123) 780 45.6
052) 0.140 (0.138–0.141) 684 44.9
061) 0.163 (0.157–0.164) 589 44.1
076) 0.198 (0.187–0.201) 484 43.2
090) 0.232 (0.215–0.235) 414 42.4
he following abbreviations are sued: CI, confidence interval; NNS, number of
2011
framework that allows the combination of family history
and the genetic profiles of the individual and his or her
relative in disease risk predictions.
A distinct advantage of our method is the flexibility and
ease that allows for any family structure and size. Because
the known risk factors are conceptualized as a continuous
variable of measurable liability, the algorithm can be easily
extended to deal with more complex pedigrees within the
same framework of liability distributions. The computa-
tion requirement is not substantially increased.
Because the prediction model is based on the variance-
explained framework, we can also readily extend the
model to handle markers in LD, haplotypes, or multilocus
genotypes (when interactions are present). The extensions
are described in detail elsewhere.7
Another feature of our approach is that not only the
affection status but also the genotype information (or
potentially other risk factor profiles) of family members
can also be incorporated in risk prediction. Formulas
were provided for risk estimates given the measurable
liability of the individual and his or her relative. We have
also extended the method of calculating Vg to continuous
predictor variables. Although the primary motivation of
the study is to incorporate genetic factors in risk predic-
tion, themethod can also be extended to incorporate other
categorical and continuous risk factors if the covariance
structures between the risk factors are specified. In addi-
tion, we suggest methods to provide age-specific disease
risk estimates over a specified period of time.Comparison with Other Risk Prediction
Approaches that Take Family History into Account
Ruderfer et al.18 recently proposed an innovative approach
to predict risk that incorporates family history and,
possibly, the relative’s genotype profiles Their method
was also based on a liability threshold model and was
applied to Crohn disease (MIM 266600) data. Our
approach, however, is largely different, and we believe it
carries numerous further advantages. To combine informa-
tion across multiple loci, the method of Ruderfer et al.18
requires computing the likelihood ratio for each locus.
This step involves complex conditional probabilities and
requires calculation of the joint genotype frequency of
the individual and family members and consideration of
all possible parental mating and transmission types. Exten-
sion of the method to more family members and complex
family structure is probablymore tedious and complicated.
In contrast, our approach is built on the concept of a
continuous measurable liability, which summarizes the
contribution for all genetic (and/or nongenetic) risk
factors. The computation is greatly simplified and exten-
sion to complex pedigree structure is very straightforward.
Our algorithm also easily handles markers in LD, haplo-
types, multiallelic markers, interactions, etc. by the appro-
priate calculation of Vg. Another advantage is that we canThe Amevisualize the distribution of predicted risk for individuals
with a family history of the disease by analytic calcula-
tions. Risk at any percentile can be readily computed.
These measures are often of interest from a public health
point of view. Importantly, we also studied age-conditional
risk estimation and the implications of our risk prediction
approach for cancer screening; these were not explored in
previous works.
Themost standard and commonly used approach for risk
prediction is probably logistic regression. Family history
can also be added as a covariate in the regression equation.
This approach is relatively straightforward and canbe easily
implemented in most statistical software. It is free of the
liability threshold model assumption. Obviously, we need
to assume the data can be fit well by the standard logistic
model (or other statistical models employed).
It is, however, difficult to deal with complex family
structures with logistic regression. Usually we just consider
whether an individual has a family history or not without
considering the detailed pedigree structure. For example,
a person might have one first-degree relative and one
second-degree relative affected with the disease but such
family history information is hard to be incorporated
into a logistic model.
Moreover, building a logistic regression model requires
information on genetic and environmental risk factors
and family history to be available for all subjects. Therefore,
a clinical samplemust be available. Such clinical studies are
often expensive and time consuming to perform because
information on family history and genotypes (or other
risk factors) must be ascertained from every individual.
Because the effect sizes and frequencies of variants can
differ across populations, these clinical studies might need
to be repeated in different populations as well. Also, such
models are less flexible; for example, it is difficult to deal
with complex family structures and update the predicted
risks when new susceptibility loci are discovered.
On the other hand, our proposed approach can model
the effect of family history by knowing only the allele
frequencies and relative risks of the susceptibility variants
and the disease heritability. These summary statistics are
usually available from published studies and public data-
bases. Raw data are not required. As such, one can combine
effect size estimates of risk factors from independent
studies or meta-analyses. Programs for implementing the
described methodologies will be available at the ‘‘Risk
prediction from family history and genetic variants’’ web-
site by H.-C.S. A web interface is also under development.
An advantage of a regression approach is that it takes
into account of the covariance structure of all predictor
variables (because the raw data is available). The risk
prediction approach based on the liability model can
also, in theory, model any categorical and continuous
predictor variables, but their covariance structure will
need to be specified, which is less straightforward.
Anothermethod to take family history into account is via
consideration of the residual familial risk.19 This residualrican Journal of Human Genetics 88, 548–565, May 13, 2011 557
familial risk is the sibling relative risk after removing the
contribution of the known susceptibility variants. The rela-
tive risk conferred by the genotype (or the aggregate relative
risk conferred by a combination of genetic variants) is
multiplied by the residual familial risk and the disease prev-
alence. This method can also combine risk factor informa-
tion from independent studies. The advantage of risk
predictionbasedon the liabilitymodel is that it canbeeasily
extended to handle arbitrary family structure and size,
whereas the extension of familial risk is not straightforward
and to our knowledge has yet to be derived.Limitations of the Prediction Model
No prediction models are perfect, and there are limitations
for our proposed risk prediction approach. There are a
number of assumptions that should be borne in mind
before clinical applications.Rare Variants
We have mainly focused on the use of common genetic
variants in prediction. Rare mutations or structural vari-
ants are usually of higher penetrance, though they usually
affect a small proportion of people. For breast cancer, rare
mutations such as those in BRCA1 (MIM 113705) and
BRCA2 (MIM 600185) have long been known to alter the
disease risk. More comprehensive reviews of the genetics
of familial breast cancer can be found elsewhere.20–23
However, these high-penetrance mutations are found in
only about 5% to 10% of all breast cancer cases.20 The life-
time risk of breast cancer for BRCA1 mutation carriers is
about 65% and for BRCA2 is about 45%.24 For comparison,
a woman with one affected first-degree relative and who is
at the top 0.3% according to the genetic risk conferred by
the 13 common variants will have the same lifetime risk.
We also observed that the highest risk in Table 4
approaches 40%. We estimated that a woman at the 98th
risk percentile who has one affected relative at the second
percentile also has a lifetime risk of approximately 45%.
We did not consider rare variants such as BRCA mutations
in the current analysis. Our proposedmethod is best suited
for those who do not harbor high-penetrance rare variants.
Numerous programs are available to predict the probability
of carrying BRCA mutations.25–27Other Breast Cancer Prediction Models
Numerous prediction models have been developed for
breast cancer, and we shall briefly review some of them
here. A detailed review of different risk assessment models
can be found elsewhere.28 The Gail model,29 which was
based on data obtained from the Breast Cancer Detection
Demonstration Project, was one of the earliest and
continues to be one of the most widely used prediction
models. The risk factors and relative risks were determined
from logistic regression. The risk factors include hormonal
factors (age atmenarche andfirst birth), numberofprevious558 The American Journal of Human Genetics 88, 548–565, May 13,breast biopsies and the number of affected first-degree rela-
tives. Anotherwell-knownmodel is theClausmodel.30 This
model was derived from complex segregation analysis from
a nested population-based case-control study and assumes
a rare autosomal dominant (AD) locus that increases suscep-
tibility to breast cancer. Only family history is used for risk
prediction. The model allows both first- and second-degree
relatives to be included and is able to adjust the risks based
on their ages at onset. An extension of the Claus model31
also allows for inclusion of ovarian cancer, bilateral breast
cancer, and more than two affected relatives. The Interna-
tional Breast Cancer Intervention Study (IBIS) or Tyrer-
Cuzick model27 combines the features of the previous two
models and accounts for both family history andother clin-
ical risk factors. It assumes two AD loci (BRCA1 and 2) and
one hypothetical low-penetrance gene. Mutation probabil-
ities of BRCA1/2 can be calculated as well.
The major differences between our model and others are
that we incorporate genotype information from common
variations and that our model is a general framework that
can also be applied to other complex diseases. Unlike most
othermodels, development of the current prediction frame-
workdoesnot require any rawdata frompopulation studies.
Our proposed model is based on the theory of the liability
threshold model, and whether the theory works well in
practice will require further validation in external datasets.
Because there are yet no empirical studies on the
combined effect of common variants and family history,
we compare the risk ratios of positive family history as pre-
dicted from the liability threshold model against those
obtained frompopulation studies.We consider a large-scale
collaborative study on breast cancer that combined indi-
vidual data from 52 epidemiological studies including
58,209 women with the disease and 101,986 controls.32
Compared to women with no affected relatives, the re-
ported risk ratios for women with one, two, or three or
more affected first-degree relatives are 1.80, 2.93, and
3.90, respectively.32 Employing the liability threshold
model, the corresponding risk ratios are 2.09, 2.94 and
3.65 respectively (the comparison group consists of women
with one unaffected female relative andwe assumed exactly
three affected relatives for the third scenario). The risk ratios
are 1.84, 2.58, and 3.20, respectively, when comparison is
made to the general population instead. These results
suggest that the liability thresholdmodel provides risk esti-
mates that agree reasonably well with empirical data.
Inclusion of other established environmental or clinical
risk factors in the prediction model will be another impor-
tant step. For breast cancer, many risk factors such as
hormonal factors and personal history of breast diseases
have been identified. As a simple solution, the relative risks
of nongenetic factors can be directly multiplied to the
current risk estimates if we assume independence of these
risk factors with known genetic variants and family
history. A similar approach was also employed in the IBIS
(Tyrer-Cuzick) model.27 Note, however, that this assump-
tion might not hold in practice.2011
The effect sizes of SNPs in this study are mainly based on
theNHGRI catalog. The risk allele frequencies,ORs, and their
corresponding confidence intervals were calculated from
a joint analysis of the discovery and replication samples. If
a replication sample was not available, then SNPs from the
discovery sample were reported. It is known that effect size
estimates are often biased upward for selected markers
passing a stringent significance threshold, a phenomenon
known as the winner’s curse33,34. The ORs used in this study
might also be overestimated because of this bias, and the re-
ported risks at different percentiles might appear to more
dispersed than they really are. Nevertheless, the bias is
unlikely to be substantial because the sample size for replica-
tion is usually large compared to the original GWAS.
We have not considered age at onset of relatives into the
prediction model. Earlier age at onset might suggest
stronger a genetic influence, which could affect the risk
estimate for relatives. There is evidence that earlier onset
age of relatives increases the risk of breast cancer.30,32
Many prediction models take this factor into account,27,30
mainly by analyzing and fitting models to actual data.
However, we do not have any raw data, and a framework
to incorporate the age at onset of relatives into the liability
threshold model is yet to be derived. One difficulty is that
it is often hard to determine whether the same set of
variants affect both the age at onset and disease risk or
whether age at onset is a separate trait that is at least
partially determined by other variants.
The calibration of a model measures how well the pre-
dicted risks agree with the actual risks and is an important
criterion to be assessed. Because of the lack of external vali-
dation data, this criterion cannot be assessed here. It
should also be noted that the risks reported here are based
on incidence and mortality data from the US (from the
SEER database) and might not be directly applicable to
other populations.
A few other assumptions are alsomade in the risk model.
We assumed proportional hazards in age-conditional risk
estimates. In other words, the hazard ratios of the risk
factors are assumed to be constant regardless of age. This
might not be true in practice because genetic variants or
family history might exert larger influences in younger
age groups. For example, it has been observed that for
breast cancer, the risk ratio conferred by positive family
history generally decreases with the woman’s age.32 Of
the SNPs for breast cancer identified to date, none of the
ORs are found to vary by age. However, the hypothesis of
age-dependent ORs is seldom explicitly tested in associa-
tion studies. To overcome this assumption, Equation 3
can in fact be modified such that the hazard ratio (R) is
function of age rather than a fixed value. We have per-
formed a simple test to investigate the effect of this
assumption on risk estimates. We extracted the age-specific
effect sizes of having relative affected with breast cancer
from the Collaborative Group on Hormonal Factors in
Breast Cancer.32 The lifetime risk estimate without the
proportional hazard assumption was 19.47%. On the otherThe Amehand, assuming a constant hazard ratio of 1.80 (the aggre-
gate effect size reported), the lifetime risk was 20.36%. For
simplicity, we assume the risk ratios are close to the hazard
ratios. The results are reasonably close, suggesting that
the assumption might not produce a substantial effect on
lifetime risk estimates.
We assumed that the effects of the SNPs are additive on
the liability scale, which is close to a multiplicative model
of ORs. There is no strong evidence for gene-gene and
gene-environmental interactions for the SNPs under study,
but this is an area that warrants further exploration. If
interactions are indeed present, they can potentially be
accommodated in our model as well because the Vg can
still be calculated (please refer to So et al.7).
We have assumed heritability refers to the variance in
liability to disease at any time in life. This might not be
true because of censoring in real studies, especially for
later-onset traits. The study design can also differ, affecting
the interpretation of heritability. We can correct this
problem by using more sophisticated methods such as
frailty models when computing heritability estimates.35
The assumptions we used are inevitable because there is
not enough data available to enable us to consider age-
specific hazard ratios or recompute heritabilities.
Another caveat to note is that the age-specific incidence
and mortality rates can only be cross-sectional. These
figures can change with time. For instance, if a disease
becomes more common in the future, the disease risks pre-
sented here will be underestimates. As a result, projection
of risk over a long period of time might be less reliable.
Implications for Targeted Prevention and Screening
We showed that a collection of susceptibility variants helps
to stratify the population into diverse risk categories,
which can be useful in delivering screening programs.
For those with a family history, the magnitudes of pre-
dicted risks are higher and the risk range is wider. It is
possible to design a more individualized screening
program that takes into account the actual predicted risks
from family history and genetic risk factors. In particular,
high-risk individuals might benefit from earlier screening.
A number of societies have issued guidelines on breast
cancer screening and prevention, for example the National
Institute for Health and Clinical Excellence (NICE) in
UK,36 the American Cancer Society,37 and the National
Comprehensive Cancer Network.38 These guidelines differ,
but in general they recommend earlier surveillance for
women at higher risks. For example, the NICE guideline
recommends mammography screening for women age
40 or older who have 10-year risks greater than 3% or life-
time risks > 17% as predicted from their family history.
Other women who do not have elevated risks are offered
mammography beginning at age 50. From this study, it is
clear that the inclusion of genetic information helps to
refine a person’s risk; for example, a woman with a positive
family history but a favorable genetic profile might not
have an elevated risk (Table 3), whereas another womanrican Journal of Human Genetics 88, 548–565, May 13, 2011 559
without a family history but who harbors multiple risk
variants might need earlier screening (Table 2). Clinical
decisions can be altered by a person’s genetic profile.
Genomic profiles can also be used in other applications
such as choosing individuals for inclusion in clinical
trials39 and determining whether chemoprophylatic
agents should be taken.40 Some interventions or screening
methods are more expensive or can carry greater side
effects (e.g., magnetic resonance imaging screening or che-
moprevention) and hence might not apply to the whole
population. It might be more efficient to target the high-
risk individuals instead.
As shown in Table 4, a woman with an affected first-
degree relative and a high-risk genotype profile might be
advised to start screening in her 30s, as deduced from the
10-year disease risk. However, practically, the relative
might not have been diagnosed by that time, especially if
the relative is a sister. In that case, the woman can be
advised to start screening as early as possible after the diag-
nosis of the relative. The data presented in the tables of this
paper are theoretical only and some flexibility might be
required when applied in real cases.
Although genomic profiling has potential to be applied
to screening and targeted prevention, the limitations and
assumptions must be carefully considered. As detailed
before, our proposed framework has a number of limita-
tions (some of which also apply to other prediction
models). It should be emphasized that external validation
is crucial to assess the performance of our model.
Even if a prediction model is well-validated, the harms
and benefits of screening must be carefully weighed
before applications. Some possible sources of harm from
mammography screening include radiation exposure,
anxiety and distress from the screening procedure (espe-
cially when the result is a false positive), additional
biopsies from false positives, and overdiagnosis.41 Over-
diagnosis can occur when early-stage breast cancer or
ductal carcinoma in situ is detected in a woman (typically
an elderly woman) who is likely to die from other causes or
when a detected early-stage lesion never advances to a clin-
ically significant cancer.11
In this study, we followed Pharoah et al.,10 who took the
10-year risk at age 50 as the threshold at which screening
has a net benefit. However, the choice of 10 years instead
of a longer or shorter term of risks is somewhat arbitrary.
One justification might be that clinical trials for mammog-
raphy screening often have a follow up of around 10 years.
Also, considering a very short-term risk (e.g., the 1-year
risk) is probably not justified because the predicted risks
will still be very close for people with diverse risk factors.
On the other hand, risk estimates over a long period of
time can be less reliable. Ideally, risk thresholds should
be determined based on a detailed analysis on the potential
harms and benefits. For example, Gail and Pfeiffer42 have
proposed a decision theoretic model for screening that
considers the losses (or gains) that result from the false
positives, false negatives, true positives, and true negatives.560 The American Journal of Human Genetics 88, 548–565, May 13,The considerations are even more complicated if the tar-
geted screening program is to be applied at the population
level. For instance, we need to consider the cost saved from
early detection and treatment of the diseases, the amount
of morbidity and mortality reduced, the cost of implemen-
tation of the program (e.g., genotyping and personnel),
and so on. Education of the public and health care profes-
sionals is also necessary.
The susceptibility variants found to date do not enable
us to predict whether an individual will develop the disease
with very high certainty; hence, it is inappropriate for
diagnosis of diseases or for determining if an invasive
procedure (such as surgery) should be performed. We
can tell the probability that one will be affected, but
these probabilities are far from 1 (definitely affected) or
0 (definitely disease-free). It is noteworthy that the very
commonly employed metric of area under the receiver
operation characteristic curve (AUC) is more suited for
evaluating the power of a test for diagnosis than the suit-
ability for targeted prevention. Hence, a relatively low
AUC does not preclude the clinical usefulness of a predic-
tion test.43,44 We have not evaluated the improvement in
predictive power by inclusion of genetic variants into a
prediction model, for example the net reclassification
improvement, AUC change, etc. Readers can refer to refer-
ence45 for a more detailed discussion on this matter.
We have not delved into a number of complexities
regarding breast cancer screening. For example, mammog-
raphy is more sensitive for women over 50 years of age,46
and the actual benefits of screening should take this factor
into account. We have not differentiated estrogen-receptor
(ER) positive and negative breast tumors. The effect size of
SNPs can differ, depending the ER status of the tumor.23
For prostate cancer, the benefits over harms for screening
are not clear yet.15 However, it is possible that targeting
high-risk men might improve the efficiency of screening.
The main aim of this study is to propose a statistical
framework to predict risks based on family history and
genomic profiles. The validity of the model will need to
be confirmed empirically in actual samples. If a large
clinical sample is available, one can directly use standard
techniques such as logistic regression to build a risk model
with genetic or other risk factors and family history as
predictors. Such models will not depend on the liability
threshold model. However, this approach also suffers
from a number of limitations as discussed previously. For
example, large clinical samples are needed, and the study
is often costly and time-consuming. It is often hard to
collect a sufficient sample size for rarer diseases and the
model is also less flexible. The framework we propose
aims to provide a reasonable estimate of the disease risk,
particularly when large clinical studies are not available,
that considers both family history and genotype profiles.
In the long run, clinical trials and long-term follow up
are required to confirm whether the targeted prevention
strategy suggested here would ultimately offer more bene-
fits than harms. In conclusion, we suggest that for some2011
diseases, such as breast cancer, by combining genetic
profiling and family history, we can stratify the population
into diverse risk categories, which can be helpful in tar-
geted disease prevention and the delivery of more individ-
ualized screening programs. We believe that it is important
to examine the potential of genetic testing for diseases on
a case-by-case basis. The usefulness of such testing will
depend on the clinical context, for example whether the
test is intended for diagnosis or targeted prevention.Appendix A
PA Formula
The PA selection formula47,48 is a generalization of regres-
sion and describes how a mean vector and covariance
matrix of a set of variables are distorted by selection on
a subset of the variables. Suppose we have a set of random
variables, partitioned into x and y. The mean vector and
covariance matrices of the variables are
m ¼

mx
my

; S ¼

Vx Cxy
Cyx Vy

:
Assume that selection is performed based on the vector
x. If the selection transforms the mean of x vector from
mx to m

x, the mean vector for y will be changed to
my ¼ my þ CyxV-1x

mx-mx

:
If the selection transforms the covariance matrix of x
from Vx to V

x, then the covariance matrix S will be
changed to
S ¼
"
Vx V

xV
-1
x Cxy
CyxV
-1
x V

x Vy-Cyx

V-1x -V
-1
x V

xV
-1
x

Cxy
#
:
Remarks on the PA Formula and an Alternative
Approach to Dealing with Selection via the Use
of Multivariate Integration
Strictly speaking, the PA formula provides only an approx-
imation to the predicted risks, although the approxima-
tion is very good in most cases. For instance, we consider
the simplest case of predicting an individual’s risk given
that he or she has one affected first-degree relative. We
assume the liabilities for the individual and the relative
are bivariate normal with a covariance equal to h/2, h being
the heritability.Pr

xind > T j x1 > T . xi > T ; y1 < T . yj
¼
Pr

xind > T ; x1 > T . xi > T ; y1 < T .
Pr

x1 > T . xi > T ; y1 < T . yj <
¼
Pr

xind > T ; x1 > T . xi > T ; y1 < T .
Pr

x1 > T . xi > T ; y1 < T . yj <
The AmeApplying PA formula, we can estimate themean and vari-
anceof the individual’s liability conditionedon the affected
relative’s liability, which is truncated normal. Because the
individual’s and the relative’s liabilities are correlated, the
individual’s liability will no longer be normal given that
the relative is affected. The deviation from normality is,
however, usually very small and can generally be neglected.
This phenomenon was first noticed by Falconer.49
Thedeviation is greater if thedisease is very rare (andhence
hasahigh liability thresholdandthedistributionconditioned
on this extreme truncated normal is very far from normality)
and the covariance between the liabilities of the relative and
the individual is large. In the special case inwhichone is inter-
ested in predicting for monozygotic twins (given that one of
them is affected) under a high heritability, the PA formula is
inaccurate and alternative approaches can be used.
An exact method for taking into account the correlation
in liabilities is the integration ofmultivariate normal distri-
butions. Fast numerical algorithms for computing normal
multivariate integrals have been developed50 and are
implemented in the R package mvtnorm.
For example, the individual’s risk given an affected first-
degree relative can be expressed as
Pr(individual affected/relative affected) ¼ Pr(individual
AND relative affected)/Pr(relative affected)
In terms of liabilities, we are interested in the probability
that the individual’s liability (xind) exceeds T given that the
relative’s liability (xrel) exceeds T. This probability can be
computed by bivariate integration,
Prðxind > T j xrel > TÞ
¼ Prðxind > T and xrel > TÞ
Prðxrel > TÞ
¼
RN
T
RN
T
f2ðxind; xrelÞdxind dxrel
1 FðTÞ
where f2 denotes the bivariate normal density.The above method can be generalized to deal with any
number of affected and unaffected relatives and the geno-
type information of the individual and other relatives.
Assume we know that i relatives are affected, j relatives
are disease-free, and the genotype profiles of k relatives are
given. For notational simplicity, denote the overall liability
of the i affected relatives as x1, x2 .xi, the overall liability
of the j disease-free relatives as y1,y2,.yj, and the measur-
able liability (the liability score from a set of known risk
variants) of the k relatives asm1,m2,.mk (the correspond-
ing random variable is denoted by M):< T ; Mind ¼ mind; M1 ¼ m1 . Mk ¼ mk

yj < T ; Mind ¼ mind; M1 ¼ m1 .Mk ¼ mk

T ; Mind ¼ mind; M1 ¼ m1 .Mk ¼ mk

yj < T jMind ¼ mind; M1 ¼ m1 .Mk ¼ mk

T jMind ¼ mind; M1 ¼ m1 .Mk ¼ mk

:
rican Journal of Human Genetics 88, 548–565, May 13, 2011 561
The multivariate distribution of x and y conditioned on
values of measurable liability can be found by a standard
result in multivariate statistics (for example see result 4.6
in Johnson and Wichern51). The theorem is restated here
for easy reference.
Let X ¼

X1
X2

be distributed as Npðm;SÞ. The mean
vector is denoted by m ¼
h
m1
m2
i
and the covariance matrix
is denoted by S ¼

S11 S12
S21 S22

with jS22j > 0. The condi-
tional distribution of X1, given that X2 ¼ x2, is normally
distributed with the following mean and covariance
Mean ¼ m1 þ S
12
S
-1
22
ðx2-m2Þ
and
Covariance ¼ S11 - S12S-122S21:
Having derived the mean and covariance matrix of the
conditional distribution of x and y, the above expression
equalsRN
T
.
RN
T
R T
N.
R T
N f1þiþj jM

xind; x1 . xi; y1 . yj

dy1 . dyj dxind dx1 . dxiRN
T
.
RN
T
R T
N.
R T
N fiþj jM

x1.xi; y1.yj

dy1 . dyj dx1 . dxi
:There are, however, several advantages of using the PA
formula. The formula involves just matrix inversion and
hence calculations can be carried out in most statistical
software and spreadsheets (such as Excel). On the other
hand, multivariate normal integration requires dedicated
computer programs, although currently the speed of
computation is also very fast. The PA approach also allows
the final results to be presented in explicit closed formulas
(as listed in the main text).Risk Prediction for an Individual with One
First-Degree Relative Affected
Suppose the individual has been genotyped on a set of
susceptibility variants. Following the above notations, we
have the following equations in the current application:
Vx ¼ 1 Vy ¼

V V
V 1

;
Cyx ¼

V=2
h=2

Cxy ¼ ½V=2 h=2 ;
and
mx ¼ 0 my ¼

0
0

One can then apply the PA formula to calculate the mean
and covariancematrix ofMind and Lind after selection on Lrel.562 The American Journal of Human Genetics 88, 548–565, May 13,my ¼ my þ CyxV-1x

mx-mx

     ¼ 0
0
þ V=2
h=2
313 ða 0Þ ¼ aV=2
ah=2
and
Vy ¼ Vy  Cyx

V-1x -V
-1
x V

xV
-1
x

Cxy
¼

V V
V 1



V=2
h=2

3 ð1 bÞ3 ½V=2 h=2 
¼

V  ð1 bÞV2=4 V  ð1 bÞðVh=4Þ
V  ð1 bÞðVh=4Þ 1 ð1 bÞh2=4

Then the second selection is performed based on the
known measurable liability of the individual (Mind). The
newmean is equal to the observed measured liability score
for the individual (mI ), whereas the new variance equals
zero because the individual now has an exact liability
score. The PA formula can be applied again, giving the
new mean and variance of the individual’s overall liability
Lind after selection. The results are given in the main text.Risk Prediction Given the Genotypes of Both
the Individual and His or Her Affected Relative
The first selection is based on the relative’s affection status.
By PA formula, after the selection on Lrel,Mrel,Mind, and Lind
has the following mean and covariance:
~m1st sel ¼
"
0
0
0
#
þ
"
V
V=2
h=2
#
ð1Þða 0Þ ¼
"
aV
aV=2
ah=2
#
and
~V 1st sel¼
"
V V=2 V=2
V=2 V V
V=2 V 1
#

2
4 VV=2
h=2
3
5ð1bÞ½V V=2 h=2 
¼
2
6666664
V ð1 bÞV2 V ð1 bÞV
2
2
V ð1 bÞVh
2
V ð1 bÞV2
2
V ð1 bÞV
2
4
V ð1 bÞVh
4
V ð1 bÞVh
2
V ð1 bÞVh
4
1 ð1 bÞh
2
4
3
7777775
:
The second selection is based on a particular value of
the measurable liability of the relative (Mrel). Suppose we
know that the relative’s measurable liability equals mR;
the variance now becomes 0 as the relative has an exact
liability score. The mean and covariance of Mind and Lind
are2011
~m 2nd sel ¼

aV=2
ah=2

þ
2
64
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2
V  ð1 bÞVh
2
3
75 1
V  ð1 bÞV2

ðmR  aVÞ
¼
2
4 mR=2ah
2
þ V  ð1 bÞVh
2
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ðmR  aVÞ
3
5
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2
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3
775:
The third and final selection is based on the actual value
of the individual’s measurable liability (Mind). Let this
actual value be mI ; the mean and variance of the individ-
ual’s overall liability are
~m final¼ ah
2
þ V  ð1 bÞVh
2
	
V  ð1 bÞV2
ðmR  aVÞ
þ 3V
4

3V
4
1
mI mR
2

¼ ah
2
 aV ½1ð1 bÞh
2½1 ð1 bÞV þ
1
2

1ð1 bÞh
1 ð1 bÞV 1

mRþmI
and
~Vfinal ¼ 1 ð1 bÞh
2
4
 ½V  ð1 bÞVh
2
4
	
V  ð1 bÞV2
 3V4 :
Risk Prediction Given the Measurable Liability
of an Affected First-Degree Relative
We have considered the case when a first-degree relative is
affected and his or her measurable liability is known.
Conditioned on these factors, the mean and variance of
the index individual’s overall liability are
~m ¼ ah
2
þ V  ð1 bÞVh
2
	
V  ð1 bÞV2
ðmR  aVÞ
and
~V ¼ 1 ð1 bÞh
2
4
 ½V  ð1 bÞVh
2
4
	
V  ð1 bÞV2
;The Amerespectively, as given in the main text. Here, we show why
higher measurable liability of the relative (mR) would lead
to a bigger risk for the index individual. Obviously, the
variance is independent of mR. We only need to consider
the sign of the coefficient associated with mR.
Note that V  ð1 bÞVh ¼ V ½1 ð1 bÞh. b is the vari-
ance of a truncated normal distribution and is between
0 and 1. We have 0 < (1  b) < 1 and 0 < h < 1 and 0 <
V < 1, hence 0 < V[1  (1  b)h] < 1 .
By a very similar argument, V  ð1 bÞV2 ¼ V ½1
ð1 bÞV , and we have
0 < ð1 bÞ < 1 and 0 < V < 1
0 < V ½1 ð1 bÞV  < 1 :
To conclude, the coefficient associated with mR is posi-
tive,
V  ð1 bÞVh
2
	
V  ð1 bÞV2
 > 0;
and higher mR would result in bigger risk for the indi-
vidual.Variance Explained for Continuous Risk Factors
We have considered the Vg for a biallelic genetic variant
before. In many cases, the risk factor is continuous. For
example, high blood pressure and lipid levels are risk
factors for type 2 diabetes. In this case, the Vg enables us
to have an idea of the contribution of the particular risk
factor to the overall variance in liability to the disease. It
also allows us to extend the risk prediction framework to
accommodate continuous predictor variables.Calculation Based on Original Vg Estimation
Approach with Finer Risk Factor Categories
Previously we consider the calculation of Vg when the risk
factor (i.e., genotype) has three categories. To extend the
calculation to the scenario involving a continuous risk
factor, we can use a straightforward approach of treating
each level of the risk factor as a distinct category and calcu-
lating the odds ratio in each category. We can set any cate-
gory with odds ratio 1. The odds ratio for another category
having a difference of h units with the baseline group is
given by exp(hb) or exp(b)h. In this case, the maximum
number of categories is the total number of subjects. The
frequency of each risk category is 1/number of subjects if
there are no two people with the same level of the risk
factor. The disadvantage is that this approach requires
raw data.
A further generalization is to assume a certain distribu-
tion of the predictor variable. For many risk factors, we
can assume a normal or log-normal distribution. We can
divide the predictor variable into arbitrarily fine categories,
and Vg can be calculated as usual. When the number of
categories is increased, the Vg should converge to the
true Vg. For simplicity, we assume the predictor variable
follows a normal distribution with a given mean andrican Journal of Human Genetics 88, 548–565, May 13, 2011 563
variance. We can divide the distribution into k bins, and
the mean in each bin is derived from a truncated normal
distribution,
EðX j za < X < zbÞ ¼ mþ s
f

za  m
s

 f

zb  m
s

F

zb  m
s

 F

za  m
s
:
where m and s are the mean and standard deviation of the
normal distribution, while za and zb are the start and end
points of the bin.
The odds ratio for each category is approximated by the
odds ratio corresponding to the mean. (If the number of
bins is large, the mean for each bin can also approximated
by the midpoint). The frequency of falling into each cate-
gory can be directly derived from the relevant cdf. For
example, if the distribution is normal, this frequency is
FðzbÞ  FðzaÞ. Then the same algorithm for calculating
Vg with only three genotype categories can be followed.
The limitation of this approach is that we need to assume
a parametric form of the predictor variable.Supplemental Data
Supplemental Data include three figures and five tables and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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